Drug Details

General Information of the Drug (ID: DR5364)
Name
Alogliptin
Synonyms
Alogliptin; 850649-61-5; UNII-JHC049LO86; Alogliptin (SYR-322); (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; JHC049LO86; CHEBI:72323; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; alogliptina; vipidia; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile; Alogliptin [INN]; alogliptine; alogliptinum; SYR322; HSDB 8203; SCHEMBL121028; CHEMBL376359; GTPL6319; BDBM16285; HY-A0023A; DTXSID90234130; AMY22119; Alogliptin pound SYR-322 pound(c); MFCD09833196; s2868; s5365; ZINC14961096; AKOS025149226; CCG-267914; CCG-267915; CS-1617; DB06203; SB20301; 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile; AC-26300; AS-19582; SW219186-1; Y1123; Q-4517; Q4734170; BRD-K83003151-057-02-4; 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile
    Click to Show/Hide
Molecular Type
Small molecule
Disease Type 2 diabetes mellitus [ICD-11: 5A11] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Clearance
The renal clearance of drug is 9.6 L/h
Half-life
The concentration or amount of drug in body reduced by one-half in 21 hours
Metabolism
The drug is not metabolised
Vd
The volume of distribution (Vd) of drug is 417 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C18H21N5O2
PubChem CID
11450633
Canonical SMILES
CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
InChI
1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
InChIKey
ZSBOMTDTBDDKMP-OAHLLOKOSA-N
CAS Number
CAS 850649-61-5
ChEBI ID
CHEBI:72323
TTD Drug ID
D0NJ5H
DrugBank ID
DB06203
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Voglibose      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Alogliptin (0.03%) and voglibose (0.001%) alone or in combination were administered in the diet to prediabetic db/db mice.
                    Experimental
                    Result(s)		 Chronic treatment with alogliptin in combination with voglibose concurrently increased active GLP-1 circulation, increased insulin secretion, decreased glucagon secretion, prevented the onset of the disease, and preserved pancreatic beta-cells and islet structure in prediabetic db/db mice.
Target and Pathway
Target(s) Dipeptidyl peptidase 4 (DPP-4)  Molecule Info  [3]
KEGG Pathway Protein digestion and absorption Click to Show/Hide
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 TGF_beta_Receptor Signaling Pathway
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6319).
Reference 2 Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab. 2010 Mar;12(3):224-33.
Reference 3 Clinical pipeline report, company report or official report of Takeda (2009).
 Download Picture         KEGG Link